Literature DB >> 11957263

Survival advantage in female patients with sickle cell anaemia.

T R Kotila1, W A Shokunbi.   

Abstract

OBJECTIVE: To evaluate the clinical and laboratory features of adult sickle cell anaemia patients in Nigeria.
DESIGN: A cross-sectional study.
SETTING: Haematology clinic of the University College Hospital, Ibadan, Nigeria.
SUBJECTS: Sixty nine adult sickle cell anaemia patients randomly sampled.
RESULTS: The mean steady state haematocrit, HbA2 and HbF were 22%, 4.6% and 7% respectively. Twenty five per cent of the patients had never received blood transfusion and a similar proportion recorded an infrequent occurrence of painful crises.
CONCLUSION: An improved survival was observed with female patients showing an age related survival advantage over the males. Persistent splenomegaly was observed less frequently in the Nigerian sickle cell population despite the high frequency of alpha thalassaemia in the region. This was thought to be due to the lower levels of HbF in this population.

Entities:  

Mesh:

Year:  2001        PMID: 11957263     DOI: 10.4314/eamj.v78i7.9012

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  4 in total

1.  Sickle cell disease in central India.

Authors:  Archana B Patel; Ambarish M Athavale
Journal:  Indian J Pediatr       Date:  2004-09       Impact factor: 1.967

2.  Autopsy findings and pattern of mortality in Nigerian sickle cell disease patients.

Authors:  Gabriel Olabiyi Ogun; Henry Ebili; Taiwo Racheal Kotila
Journal:  Pan Afr Med J       Date:  2014-05-08

3.  Sickle Cell Disease Clinical Trials and Phenotypes.

Authors:  Chinedu A Ezekekwu; Taiwo R Kotila; Titilola S Akingbola; Guillaume Lettre; Victor R Gordeuk; Richard S Cooper; Michael R DeBaun; Baba Inusa; Bamidele O Tayo
Journal:  J Trop Dis Public Health       Date:  2018-04-08

4.  ADDICTION OR PSEUDOADDICTION IN SICKLE CELL DISEASE PATIENTS: TIME TO DECIDE - A CASE SERIES.

Authors:  T R Kotila; O E Busari; V Makanjuola; O R Eyelade
Journal:  Ann Ib Postgrad Med       Date:  2015-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.